3D Liver Spheroid Model for NASH and Fibrosis Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liver fibrosis models, including 2D cultures of hepatic stellate cell lines and animal experiments, fail to accurately represent liver morphology and physiology, limiting their use in preclinical applications and high-throughput screening, and lack the inclusion of key cell types necessary for studying human liver diseases like NASH and fibrosis.
Innovation Solution
A 3D spheroidal microtissue model is developed comprising primary human hepatocytes, Kupffer cells, and sinusoidal endothelial cells, cultured in a specific medium without growth factors, retinol, and fatty acids, which mimics the basal state and can be induced to represent steatotic or fibrotic states, suitable for high-throughput screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If 2D cultures of hepatic stellate cell lines are used, then the model is simple to establish, but it fails to accurately represent liver morphology and physiology
Solution Approach 1:
The patent transitions from 2D culture to 3D spheroidal microtissue architecture, enabling cells to self-organize into a three-dimensional structure that better mimics in vivo liver tissue organization, morphology, and physiological functions while maintaining ease of establishment through simple hanging drop culture methods
Solution Approach 2:
The patent combines multiple liver cell types (hepatocytes, hepatic stellate cells, Kupffer cells, and sinusoidal endothelial cells) into a single co-culture spheroidal microtissue system, creating a more comprehensive and physiologically relevant liver model that captures cell-cell interactions present in native liver tissue
2Reliability
If animal experiments are used, then the model provides comprehensive liver physiology, but it requires significant resources and time
Solution Approach 1:
The patent creates an in vitro copy of liver tissue architecture and physiology through 3D spheroidal microtissues that replicate key liver cell types, their spatial organization, and functional interactions, providing a resource-efficient alternative to animal experiments while maintaining physiological relevance
Solution Approach 2:
The patent changes the scale and complexity parameters by creating microtissues with controlled cell compositions and ratios that mimic liver physiology at a micro-scale, enabling high-throughput screening capabilities while reducing resource requirements compared to whole-animal models
3Reliability
If 3D spheroid cultures are used, then the model improves physiological relevance, but it lacks complete reconstitution of liver organoids with all major cell types
Solution Approach 1:
The patent enables cells to self-organize and self-assemble into functional 3D spheroidal microtissues through simple hanging drop culture or low adherence well methods, where cells spontaneously form spheroids with appropriate spatial organization and cell-cell interactions without complex manual assembly or specialized equipment
4Ease of operation
If HSC are cultured in 2D, then the culture is easy to maintain, but HSC activate into myofibroblasts due to interaction with the culture dish
Solution Approach 1:
The patent moves HSC from 2D planar culture surfaces to 3D spheroidal microtissues, eliminating direct contact with culture dish surfaces that trigger activation, while maintaining ease of culture maintenance through simple hanging drop or low adherence well protocols that preserve HSC quiescence
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present invention relates to an in vitro testing platform for the study of metabolic liver disease and related therapeutic strategies, composed of an artificial spheroidal microtissue comprising at least hepatocytes and hepatic stellate cells, and at least one type of hepatic inflammatory cells and further medium and reagents capable to establish and simulate different stages of metabolic liver disease and their progression and testing preventive and therapeutic strategies by pharmacological and/or dietary interventions.